Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
This study has been completed.
Study NCT00591370   Information provided by Memorial Sloan-Kettering Cancer Center

First Received on December 26, 2007.   Last Updated on November 10, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
Temozolomide (TMZ)
Additional drug interventions recognized in this trial
Dacarbazine
Temozolomide
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
Schering-Plough


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services